This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Genomic Health (GHDX), BioCartis Extend Deal to Urology
by Zacks Equity Research
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) impressive Q3 results can be attributed to the Subscription Service segment's solid performance. An upbeat FY19 guidance instills investor optimism in the stock
5 Stocks to Gain as Fed Chair "Blinks" on Rates
by Swarup Gupta
Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.
Medtronic (MDT) Tops Q2 Earnings on Strong Segmental Growth
by Zacks Equity Research
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down
by Zacks Equity Research
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.
Earnings Estimates Rising for Genomic Health (GHDX): Will It Gain?
by Zacks Equity Research
Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genomic Health (GHDX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
Genomic Health (GHDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Genomic Health (GHDX) delivered earnings and revenue surprises of 400.00% and 7.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Invest in GNC Holdings (GNC) Right Now
by Zacks Equity Research
GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.
Amedisys to Buy Compassionate Care Hospice, Share Price Down
by Zacks Equity Research
Amedisys (AMED) adopts initiatives to boost hospice business. It expects to become the third-largest hospice provider in America with the latest buyout.
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Genomic Health's Test Gets Favored by New NCCN Guidelines
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.
Genomic Health's New Data on Oncotype DX GPS to Boost Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.
Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology
by Zacks Equity Research
With the rising need for AP and molecular oncology services in healthcare, we consider the acquisition of PhenoPath by Quest Diagnostics (DGX) to be well-timed and a strategic fit for its portfolio.
Women Health a Prime Concern Worldwide: 3 Stocks in Focus
by Zacks Equity Research
Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.
Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.
Genomic Health Prostate Cancer Business Solid, Cost Woes Stay
by Zacks Equity Research
Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.
Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.
Genomic Health (GHDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Genomic Health (GHDX) delivered earnings and revenue surprises of 271.43% and 4.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health's (CAH) unique portfolio of Medical and Pharmaceutical offerings will lend it a competitive edge in the MedTech space. However, the company faces sluggishness in the exam-gloves unit.
Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label
by Zacks Equity Research
Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
We are upbeat about Abbott's (ABT) synergies from Alere buyout in the form of solid Rapid Diagnostics revenues. Emerging market performance has been promising.
Can the Rally in Genomic Health (GHDX) Shares Continue?
by Zacks Equity Research
Genomic Health, Inc. (GHDX) has been on the move lately as the stock has risen by 13.5% in the past four weeks, and it is currently trading well above its 20-Day SMA